Grupo Fisiopatoloxía Endócrina, Nutricional e Médica (FENM): Envíos recentes
Mostrando ítems 46-50 de 117
-
Clinical implications of epithelial cell plasticity in cancer progression
(Elsevier, 2015)[Abstract] In the last few years, the role of epithelial cell plasticity in cancer biology research has gained increasing attention. This concept refers to the ability of the epithelial cells to dynamically switch between ... -
Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor
(Elsevier, 2015-03)[Abstract] Enzalutamide (MDV3100), an androgen receptor-signalling inhibitor, represents the most recent compound added to the therapeutic armamentarium for the treatment of metastatic castration-resistant prostate cancer ... -
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
(Oxford, 2015-03-26)[Abstract] Background. Patients with cardiovascular (CV) disease have an increased circulating angiotensin-converting enzyme 2 (ACE2) activity, but there is little information about changes in ACE2 in chronic kidney disease ... -
Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors
(Elsevier, 2015-09-10)[Abstract] Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are overexpressed in the majority of renal cell carcinomas. This characteristic has supported the rationale of targeting VEGF-driven tumour ... -
Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
(BioMed Central, 2015-07-04)[Abstract] Background. Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors or antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine ...